^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    LightMix® BRAF V600E/K Kit

    Company:
    Roche
    Type:
    CE Marked
    Related tests:
    Evidence Level:
    Resistant: B - Late Trials

    [BRAF V600E-Colorectal Cancer-cetuximab]

    Source:
    J Clin Oncol
    Test:

    LightMix® BRAF V600E/K Kit

    Title:
    Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
    Excerpt:
    BRAF V600E mutation indicated poor prognosis in patients with KRAS wild-type disease in both treatment groups, with those whose tumors carried BRAF mutations having a worse outcome for all efficacy end points compared with those whose tumors were wild-type (Table 3; Fig 2C).
    Secondary therapy:
    FOLFIRI
    DOI:
    10.1200/JCO.2010.33.5091
    Trial ID:
    CRYSTAL